Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine

Exclusion Criteria

• •1. Previous treatment with B-cell targeted therapies (e.g., rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab)
• •2. Any previous treatment with alemtuzumab, cladribine, cyclophosphamide, mitoxantrone, azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, total body irradiation, or bone marrow transplantation
• •3. Medical, psychiatric, cognitive, or other conditions that, in the investigator's opinion, compromise the patient's ability to understand the patient information, to give informed consent, or to complete the study
• •4. Patients that receive immunosuppressive treatment for diseases other than MS or that receive long-term corticosteroid treatment
• •5. Patients that received apheresis procedures 6 weeks prior to vaccination or in-between vaccination and DMT initiation
• •6. Systemic high dose corticosteroid therapy within 6 weeks prior to vaccination or in-between vaccination and DMT initiation
• •7. Patients with verified infection by human-immunodeficiency-virus or hepatitis-c-virus
• •8. Patients with major impairment of the blood coagulation system including therapy with anticoagulants
• •9. Patients with known chicken egg allergy